Currently, limited data exist on the role of tacrolimus (FK506) in pediatric allogeneic marrow transplantation. Forty-one patients who received tacrolimus as prophylaxis were reviewed, with a median age of 9 years (range 0.2-16 years). Twenty-one patients underwent related donor transplants and 20 underwent unrelated donor transplants. All patients received tacrolimus beginning the day prior to transplant at a dose of 0.03 mg/kg/day by continuous i.v. infusion. When clinically possible, patients were switched to oral therapy in two divided doses, at four times the intravenous dose. Tacrolimus levels were monitored twice a week, and dosages adjusted to maintain serum levels 5-15 ng/ml. Common adverse effects included hypomagnesemia (98%), hypertension (49%), nephrotoxicity (34%), and tremors (32%). Less common side-effects (Ͻ10% cases) included seizures and hyperglycemia. The median time to ANC recovery (ANC Ͼ500 × 10 6 /l) was 15 days. For the related donor group, the incidence of grade II-IV acute GVHD was 33%, and grade III-IV GVHD 19%. For the unrelated donor group, the incidence of grade II-IV acute GVHD was 55%, and grade III-IV GVHD 30%. Overall, tacrolimus therapy was well tolerated as prophylaxis for acute GVHD in pediatric patients undergoing allogeneic transplantation. Bone Marrow Transplantation (2000) 26, 161-167.
the risk and severity of acute GVHD remains an important area of research in hematopoietic cell transplantation.
Tacrolimus (FK506) is a macrolide lactone discovered in 1984 from the fermentation broth of Streptomyces tsukubensis. 1 Tacrolimus has potent inhibitory effects on T cell activation through down-regulation of IL-2 gene expression. [2] [3] [4] Tacrolimus binds to an immunophilin, FKbinding protein (FK-BP12), to form a complex which inhibits the phosphatase activity of calcineurin. 5, 6 Inhibition of calcineurin directly blocks the translocation of a nuclear transcription factor (NFAT) essential for IL-2 gene expression.
The efficacy of tacrolimus in the prevention of graft rejection following solid organ transplantation has been well established. [7] [8] [9] [10] The use of tacrolimus to prevent acute GVHD in adult recipients of marrow transplants has now been reported in multiple trials.
11 -23 However, clinical experience using tacrolimus in pediatric marrow transplant trials remains limited. 24, 25 Based on clinical observations in the adult population, our center subsequently examined the use of tacrolimus for the prevention of graft-versus-host disease in recipients of pediatric stem cell allografts.
Methods
Tacrolimus was administered to all patients at an initial starting dose of 0.03 mg/kg/day, administered intravenously, beginning day −1 of transplantation. The dose of tacrolimus was calculated according to the patient's lean body weight. Patients received intravenous tacrolimus therapy until they could reliably receive oral medications post transplant. At that time, patients were switched to an oral dose calculated at four times their current intravenous dose. The oral dose was administered in two divided doses, every 12 h.
Tacrolimus steady-state concentrations (while on intravenous therapy), or tacrolimus trough concentrations (while on oral therapy), were measured by IMx assay (Abbott, Abbott Park, IL, USA) on whole blood. Tacrolimus whole blood concentrations were obtained on day +1 on all patients, twice weekly while an inpatient, and then weekly as an outpatient during the first 90 days post transplant. The target concentration range for tacrolimus was 5-15 ng/ml during the first 90 days post transplant. In the absence of GVHD, tacrolimus was then tapered by 25% per month, and discontinued by day 180. Patients with acute GVHD continued to receive tacrolimus at the discretion of the investigator.
Dose modifications for tacrolimus were made if drug concentrations were Ͻ5 ng/ml or Ͼ15 ng/ml. Dose modifications were also made in patients who developed a serum creatinine Ͼ2 × baseline. Dose modifications were not made based upon serum hepatic transaminase or total bilirubin measurements. Patients with no specific contraindications also received methotrexate, 15 mg/m 2 on day 1, and 10 mg/m 2 on day 3, 6, and 11.
Adverse events analysis
The presence of nephrotoxicity was defined as a serum creatinine Ͼ2 × baseline pre-transplant value. Hypertension was defined as a systolic blood pressure Ͼ2 standard deviations above the mean for age, or the need for anti-hypertensive therapy. Hepatotoxicity was defined by an elevation of serum transaminases Ͼ4 × normal, or a serum total bilirubin level у2.0 mg/dl. Hepatic veno-occlusive disease was defined by previously described criteria. 26 Hypomagnesemia was defined as a magnesium level р1.4 mg/dl.
Grading of GVHD
Acute GVHD was graded according to Glucksberg criteria. 27 Chronic GVHD was categorized according to criteria described by Shulman et al. 28 Biopsies were obtained when clinically indicated, but were not required for a patient to be determined to have acute or chronic GVHD.
Statistical methods
The primary endpoints for the study were the development of grade II-IV acute GVHD, and the time to occurrence of acute GVHD. The main variable under investigation was the concentration of tacrolimus obtained in whole blood measurements. The relationship of these primary endpoints with whole blood tacrolimus concentrations were analyzed using a Cox proportional hazards model, whereby time to grade II-IV acute GVHD was censored by death, or relapse. 23 For each day and for each patient who was still on study, the mean tacrolimus level of the previous 14 days was calculated. Tacrolimus level was included as a timedependent covariate representing the mean level of all available values over the previous 14 days. Missing values were imputed by carrying the previous day's mean forward. Two secondary analyses were also performed. A non-parametric Wilcoxon log-rank test was used to compare the mean tacrolimus level of patients with acute GVHD to those without acute GVHD. A Kaplan-Meier analysis was performed, showing separate time to incidence curves for related and unrelated donors. The donor status curves were compared using a log-rank test. The time to engraftment was defined as the first of three consecutive days with an absolute neutrophil count (ANC) Ͼ500 × 10 6 /l.
Results
Forty-one pediatric patients (age р16 years) were treated at the University of Michigan Medical Center between May 1996 and August 1998 ( Table 1) . Sources of stem cells were bone marrow in related donors (11 patients) and all unrelated donors (20 patients). G-CSF-mobilized peripheral blood stem cells (PBSC) were used in 10 of the 21 related donor cases.
Thirty-seven of 41 patients received tacrolimus in combination with short-course methotrexate. These 37 patients received a median of 87% (mean 83%) of the scheduled methotrexate dose. The day 6 methotrexate dose was the most commonly reduced dose of methotrexate. Three patients received methylprednisolone (0.5 mg/kg/day, from day +7 to +28) in place of methotrexate. One patient received tacrolimus monotherapy.
Tacrolimus blood levels
The mean duration of intravenous tacrolimus therapy was 16 days. Thirty-seven of 41 (90%) patients completed 3 months of therapy with tacrolimus. Thirty-four of 41 (83%) patients completed 6 months of therapy with tacrolimus. Seven patients either relapsed or died prior to completing 6 months of tacrolimus therapy. Initial tacrolimus concentrations were obtained on day 1 post transplant (48 h after initiation of the tacrolimus infusion). Tacrolimus concentrations on day 1 were subtherapeutic (Ͻ5 ng/ml) in four of 41 (10%) patients, within the target range in 31 (75%) patients, and greater than 15 ng/ml in six (15%) patients. For the entire study population, the mean tacrolimus concentration during the first 28 days post transplant was 10.6 ng/ml.
Mean tacrolimus blood levels were also determined during two time intervals, days 1-7 and days 1-14 post transplant. For recipients of related donor transplants, no correlation was noted between the incidence of acute GVHD and tacrolimus concentration ( Table 2 ). For unrelated donor recipients, however, a correlation between mean tacrolimus concentration (day 1-7 and day 1-14 post transplant) and acute GVHD was noted (Table 2) . Lower tacrolimus levels within the first 2 weeks post transplant were associated with a higher incidence of acute GVHD in unrelated donor recipients. A Cox proportional hazards model using the mean tacrolimus level over the previous 14 days as a timedependent co-variate was then used to analyze the effects of tacrolimus concentration and donor type (related or unrelated) on the occurrence of grade II-IV acute GVHD. Using this model, no association was noted between tacrolimus concentration and the occurrence of acute GVHD (P value, 0.172).
Adverse events
Hypomagnesemia was the most frequent adverse advent associated with tacrolimus administration (Table 3 ). The median time to onset of hypomagnesemia was 13.5 days. Thirteen (32%) patients developed hypomagnesemia within the first week post transplant, and 33 (80%) within the first month post transplant. Magnesium supplementation was required in 40 of 41 cases during the administration of tacrolimus. Patients with mean tacrolimus levels of 5-10 ng/ml within the first month post transplant were less likely 
ALL = acute lymphocytic leukemia; ANLL = acute non-lymphocytic leukemia: CML = chronic myelogenous leukemia; NHL = non-Hodgkin's lymphoma; MDS = myelodysplasia; SCIDs = severe combined immunodeficiency; TBI = total body irradiation; GVHD = graft-versus-host disease; MNC = mononuclear cell dose.
Bone Marrow Transplantation to develop hypomagnesemia than patients with mean tacrolimus levels Ͼ10 ng/ml. Hypertension was observed in 20 (49%) patients during the first 6 months post transplant. In nine cases, the hypertension occurred prior to engraftment, within the first 3 weeks post transplant. In the remaining 11 cases, the onset of hypertension coincided with the administration of steroid therapy for the treatment of acute GVHD. In seven of 20 cases, the hypertension was associated with an elevation of serum creatinine level to Ͼ2 × baseline. The mean tacrolimus level at the time of institution of antihypertensive therapy was 9.7 ng/ml.
Fourteen patients developed nephrotoxicity (defined as an elevation of serum creatinine Ͼ2 × baseline) during the 6 month post-transplant period. The median time to onset of nephrotoxicity was 18 days (range 9-171 days). The mean tacrolimus level at the onset of nephrotoxicity was 10.9 ng/ml. Eleven patients developed peak serum creatinine levels у1.5 mg/dl within the first 6 months post transplant. Three (7%) patients required hemodialysis during the first 180 days post transplant. In two of these cases, hemodialysis was begun while patients were receiving therapy for grade III-IV acute GVHD. In the remaining case, hemodialysis was begun on day 9 post transplant in association with multi-organ failure.
Neurotoxicity was mild for the majority of patients treated. Tremors were noted in 13 (32%) cases. In seven of 13 cases, these tremors were noted in association with hypomagnesemia, and responded to correction of the hypomagnesemia. Two of 41 (5%) patients developed seizures while on therapy with tacrolimus. In the first case, a focal complex seizure developed in conjunction with sepsis, renal failure, hepatic veno-occlusive disease, and grade IV GVHD on day 23 post transplant. No electrolyte abnormalities were noted at the time of the seizure. The patient's tacrolimus level at the time of the seizure was 6.8 ng/ml. Further investigations, including cerebrospinal fluid analysis, MRI, and CT scan were negative. The patient experienced no further seizures despite continuation of the tacrolimus. In the second case, a generalized tonic-clonic seizure developed on day 40 post transplant. Blood cultures obtained at the time were positive for Klebsiella. Neurological evaluation including cerebrospinal fluid analysis, and MRI were negative, and serum electrolytes were normal. The tacrolimus level was 9.7 ng/ml at the time of the seizure. The tacrolimus was discontinued. The patient was begun on anticonvulsant therapy and no further seizures were noted.
Hepatic veno-occlusive disease (VOD) was noted in six of 41 patients (15%). No thrombolytic therapy was required in any patient. No deaths were attributable to VOD. The hepatic VOD resolved in all six cases. The mean tacrolimus level (day 1-28) for patients who developed VOD was 10.1 ng/ml.
Overall, six patients developed CMV infection (based upon a positive CMV pp65 antigenemia assay or positive CMV PCR assay) within 180 days post transplant. Two of the six patients developed symptomatic CMV disease, documented on day 32 and day 57 post transplant, respectively.
Oral mucositis was noted in all patients during the first 2 weeks post transplant. Grade 1 mucositis was noted in 11 (27%) patients, grade 2 in 17 (41%) patients, grade 3 in 11 (27%) patients, and grade 4 in two (5%) patients. There was no statistical difference in tacrolimus levels between patients who developed grade 3-4 mucositis vs patients who developed grade 1-2 mucositis (data not shown).
Hyperkalemia and hyperglycemia related to tacrolimus therapy were infrequent. No patient developing hyperkalemia required any medical management other than adjustment of intravenous fluids or TPN formulations. Three patients required insulin therapy for hyperglycemia, each case associated with steroid therapy for the treatment of acute GVHD.
No cases of hemolytic uremic syndrome (HUS), or thrombotic thrombocytopenic purpura (TTP) were observed. No cases of pancreatitis were observed. No signs of hirsutism were noted in any patient during their tacrolimus therapy, including those patients who were treated for longer than 6 months.
Engraftment
The median time to ANC recovery (ANC Ͼ500 × 10 6 /l) was 15 days (range 10-22), with a mean time to ANC recovery of 16 days. Patients who underwent related donor transplants had a median time to ANC recovery of 14 days vs 16 days for patients undergoing unrelated donor transplants. The median time to ANC recovery for patients undergoing peripheral stem cell transplants was 14 days. 
Acute graft-versus-host disease
The actuarial risks of acute graft-versus-host disease are noted in Table 4 . Eighteen of 41 patients (44%) developed grade II-IV acute graft-versus-host disease (Figure 1 ). The median time of onset of acute GVHD was 20 days (range . Seven of 21 (33%) patients who received related donor transplants developed grade II-IV acute graft-versushost disease, and 4/21 (19%) developed grade III-IV acute graft-versus-host disease. In the related donor group, four of 11 (36%) marrow recipients, and three of 10 (30%) PBSC recipients developed grade II-IV acute GVHD. Grade III-IV acute GVHD was noted in two of 11 (18%) related marrow and two of 10 (20%) related PBSCT. In the unrelated donor group, 11 of 20 (55%) patients developed grade II-IV acute graft-versus-host disease, and six (30%) patients developed grade III-IV acute GVHD. The organ sites associated with grade II-IV acute graftversus-host disease included eight patients with only skin involvement, seven patients with skin and gastrointestinal involvement, and three patients with skin, hepatic, and intestinal involvement. Acute GVHD was histologically confirmed by gastrointestinal biopsy in all cases of intesti- nal involvement. No liver biopsies were obtained. Methylprednisolone (2 mg/kg/day) was used as front-line therapy in all cases of grade II-IV acute GVHD. Three patients were treated with steroids alone, nine patients received steroids plus antithymocyte globulin, four patients received steroids, antithymocyte globulin, plus mycophenolate mofetil, and two patients were treated with a combination of steroids plus monoclonal antibody therapy. In all cases, patients continued their tacrolimus during their treatment for acute GVHD. Five of the nine patients who developed grade III-IV acute GVHD are alive (250-600 days post transplant).
Chronic graft-versus-host disease
Six recipients of unrelated donor grafts were not evaluable for chronic GVHD due to relapse or death prior to day 100. Fifteen of 35 (43%) patients developed chronic graftversus-host disease, all of whom had been followed for at least 300 days post transplant. Four of 11 (36%) recipients of related marrow developed chronic GVHD. Five of 10 (50%) recipients of allogeneic PBSCT developed chronic GVHD (including two with de novo chronic GVHD). Six of 14 (43%) recipients of unrelated donor marrow developed chronic GVHD. The actuarial probability of developing chronic GVHD by 180 days post transplant was 43.1% (95% confidence interval 0.246-0.577). Twelve of the 15 cases of chronic GVHD were categorized as extensive, and three as limited. Hepatic chronic GVHD was diagnosed in seven cases, pulmonary GVHD in three cases, and skin GVHD in 15 cases. All cases of hepatic involvement were based upon clinical findings and laboratory parameters. No hepatic biopsies were performed. One patient died as a result of complications related to chronic GVHD. All patients with chronic GVHD were treated with steroids while continuing their tacrolimus. Tapering of the tacrolimus was not begun in patients until their chronic GVHD was stable for a minimum of 3 months.
Survival
Thirty-one (76%) of patients were alive 10 to 30 months post transplant. Of 32 patients transplanted for malignant conditions, 21 remain in complete remission 10-26 months post transplant. Of the nine patients transplanted for nonmalignant conditions, eight were alive 14 to 25 months post transplant. For patients with malignancies, the KaplanMeier estimate of relapse-free survival at 1 year is 68.4% (95% Cl, 53.3-83.5%). The Kaplan-Meier estimate of overall survival (for all patients) at 1 year is 79.4% (95% Cl, 66.6-92.2%). Five patients died from leukemic relapse (days 80, 125, 136, 277, and 671). Four patients died from grade III-IV acute GVHD (days 49, 70, 97, and 149). One patient died from multi-organ failure on day 15 post transplant, prior to engraftment.
Discussion
There have been 12 published reports that have evaluated the role of tacrolimus for the prophylaxis of acute Bone Marrow Transplantation GVHD. 11, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] 25 Six reports were studies in related donor transplantation, and six were studies in unrelated donor transplantation. Only one report has been limited to pediatric patients, involving 10 recipients of mismatched unrelated cord blood. 25 The major adverse effects previously reported with tacrolimus have included nephrotoxicity, neurotoxicity, hyperglycemia, and hypertension. [29] [30] [31] [32] Other commonly reported side-effects include microangiopathic hemolytic anemias, 33 hyperkalemia, 34 hypomagnesemia, 35 and hypercholesterolemia. 36 Unlike cyclosporine, tacrolimus rarely causes gingival hyperplasia or hirsutism.
In this pediatric trial, both intravenous and oral tacrolimus were extremely well tolerated. The single most common adverse effect was the occurrence of hypomagnesemia, seen in 98% of the study population. The occurrence of hypomagnesemia correlated with higher tacrolimus levels. In contrast to published adult trials, hyperglycemia was not a common complication in this study.
Historically, the incidence of tacrolimus associated nephrotoxicity has ranged from 32-93% in adult related donor transplants trials, 11, 12, 15 and 63-88% in adult unrelated donor transplants. [19] [20] [21] In this trial, 14 (34%) patients developed a serum creatinine Ͼ2 × baseline during the initial 6 month post-transplant period. The overall lower incidence of nephrotoxicity in the current report may be related to the lower levels of tacrolimus (5-15 ng/ml) that were maintained in our study population. Wingard et al 23 reported an increased risk of nephrotoxicity when whole blood levels of tacrolimus exceeded 20 ng/ml. Patients in our trial rarely exceeded whole blood levels Ͼ20 ng/ml. In the event that a patient's whole blood level exceeded 20 ng/ml, dosage adjustments were made in our trial.
Neurotoxicity has been a common side-effect in adult studies using tacrolimus. [30] [31] [32] Clinical manifestations have ranged from mild tremors, headaches, or mild paresthesias to more severe manifestations such as aphasia, paralysis, or seizures. The neurotoxicity noted in our pediatric trial was generally mild, manifested mainly as tremors in 32% of the patients. Paralysis, aphasia, somnolence, and cranial nerve dysfunction were not seen in this study. Symptoms such as paresthesias or headaches, though not directly noted in this study, could be potentially difficult to identify in a pediatric population. Tacrolimus is a highly lipophilic agent that can penetrate the central nervous system. Only two patients developed a seizure during their therapy with tacrolimus. In both cases, the tacrolimus level was Ͻ10 ng/ml at the time of the seizure.
The incidence of hypertension in this study was comparable to reported rates of 21-63% in related donor and unrelated donor trials using tacrolimus. 11, 12, 15, [19] [20] [21] As in those trials, hypertension was most common in patients on steroid therapy. The occurrence of hemolytic uremic syndrome (HUS), or thrombotic thrombocytopenic purpura (TTP) previously reported in adult transplant recipients 37, 38 was not seen in our patient population.
Tacrolimus, in combination with short course methotrexate, appeared to be effective prophylaxis for the prevention of acute GVHD in patients undergoing allogeneic transplantation. The overall incidence of grade II-IV acute GVHD for the related donor population (33.0%) was com-Bone Marrow Transplantation parable to that reported by Ratanatharathorn et al 18 (31.9%). For unrelated donor transplants, the incidence of grade II-IV acute GVHD (55%) was similar to published adult trials by Nash et al, 19 and Devine et al. 21 When compared to published reports using cyclosporine and methotrexate as prophylaxis for acute GVHD, the current therapy with tacrolimus and methotrexate appears at least as efficacious. [39] [40] [41] [42] [43] [44] However, there are few reports that examine the use of cyclosporine plus short course methotrexate in a strictly pediatric population (р16 years). Peters et al 42 recently noted the wide variation in cyclosporin prophylaxis that is currently in use in pediatric stem cell transplantation. The standardization of tacrolimus use in pediatric transplantation will ultimately be required as well. A randomized prospective trial comparing cyclosporine plus methotrexate to tacrolimus plus methotrexate in pediatric patients is currently under development, and will address this issue further.
The correlation of tacrolimus levels with the incidence of acute GVHD has been examined in previous adult trials. Using a time-dependent covariate analysis, no significant correlation between tacrolimus concentration and the risk of acute GVHD has been found in sibling donor recipients 23 or in unrelated donor recipients. 45 Using a similar timedependent covariate analysis, we likewise could not detect a relationship between the whole blood tacrolimus concentration and the incidence of acute GVHD. On the other hand, we found significantly lower tacrolimus levels during the first 7 and 14 days post transplant in unrelated donor recipients who developed acute GVHD (when compared to those who did not develop acute GVHD). For unrelated donor recipients, this suggests the importance of tacrolimus blood level monitoring at a time when clonal T cell expansion may be most crucial for the development of acute GVHD.
In summary, the use of tacrolimus for the prevention of acute graft-versus-host disease in pediatric patients undergoing hematopoietic stem cell transplantation appears to be a well tolerated and effective therapy. The major adverse effects included hypomagnesemia (98%), hypertension (49%), nephrotoxicity (34%), and tremors (32%). The incidence of neurotoxicity was lower when compared to adult trials. For pediatric patients undergoing related donor transplantation, tacrolimus levels of 5-15 ng/ml provided adequate prophylaxis for acute GVHD. However for pediatric recipients of unrelated donor transplants, mean tacrolimus levels of 15 ng/ml in the first 2 weeks provided improved prophylaxis for the prevention of acute GVHD.
